Last reviewed · How we verify
Azithromycin + Metronidazole
Azithromycin + Metronidazole is a Macrolide antibiotic + Nitroimidazole antibiotic combination Small molecule drug developed by Sheikh Zayed Medical College. It is currently FDA-approved for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Pelvic inflammatory disease. Also known as: Azanil, Flagyl.
Azithromycin inhibits bacterial protein synthesis while metronidazole disrupts anaerobic bacterial DNA, providing broad-spectrum antimicrobial coverage.
Azithromycin and metronidazole are a combination of two small molecule DNA inhibitors used to treat various conditions, including bacterial vaginosis. They are also being studied in clinical trials for their potential to prevent malnutrition in pregnancy and treat related conditions such as stunting.
At a glance
| Generic name | Azithromycin + Metronidazole |
|---|---|
| Also known as | Azanil, Flagyl |
| Sponsor | Sheikh Zayed Medical College |
| Drug class | Macrolide antibiotic + Nitroimidazole antibiotic combination |
| Target | Bacterial 50S ribosome (azithromycin); anaerobic bacterial DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin is a macrolide antibiotic that binds to the bacterial 50S ribosomal subunit to inhibit protein synthesis, effective against gram-positive and some gram-negative organisms. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic bacteria, damaging their DNA and causing cell death. Together, this combination provides synergistic coverage against mixed aerobic and anaerobic infections.
Approved indications
- Mixed aerobic-anaerobic bacterial infections
- Intra-abdominal infections
- Pelvic inflammatory disease
- Polymicrobial infections
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Metallic taste (metronidazole)
- Headache
- Vomiting
Key clinical trials
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever (PHASE4)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD) (PHASE2)
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies (PHASE4)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- Flapless Surgical Treatment of Peri-implantitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin + Metronidazole CI brief — competitive landscape report
- Azithromycin + Metronidazole updates RSS · CI watch RSS
- Sheikh Zayed Medical College portfolio CI
Frequently asked questions about Azithromycin + Metronidazole
What is Azithromycin + Metronidazole?
How does Azithromycin + Metronidazole work?
What is Azithromycin + Metronidazole used for?
Who makes Azithromycin + Metronidazole?
Is Azithromycin + Metronidazole also known as anything else?
What drug class is Azithromycin + Metronidazole in?
What development phase is Azithromycin + Metronidazole in?
What are the side effects of Azithromycin + Metronidazole?
What does Azithromycin + Metronidazole target?
Related
- Drug class: All Macrolide antibiotic + Nitroimidazole antibiotic combination drugs
- Target: All drugs targeting Bacterial 50S ribosome (azithromycin); anaerobic bacterial DNA (metronidazole)
- Manufacturer: Sheikh Zayed Medical College — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Mixed aerobic-anaerobic bacterial infections
- Indication: Drugs for Intra-abdominal infections
- Indication: Drugs for Pelvic inflammatory disease
- Also known as: Azanil, Flagyl
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing